Amgen, Inc. (AMGN)
443.84
+4.51
(+1.03%)
USD |
NASDAQ |
Aug 24, 16:00
444.00
+0.16
(+0.04%)
After-Hours: 20:00
Amgen Net Income (Quarterly) : 2.375B for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.375B |
| March 31, 2026 | 1.819B |
| December 31, 2025 | 1.333B |
| September 30, 2025 | 3.216B |
| June 30, 2025 | 1.432B |
| March 31, 2025 | 1.73B |
| December 31, 2024 | 627.00M |
| September 30, 2024 | 2.83B |
| June 30, 2024 | 746.00M |
| March 31, 2024 | -113.00M |
| December 31, 2023 | 767.00M |
| September 30, 2023 | 1.73B |
| June 30, 2023 | 1.379B |
| March 31, 2023 | 2.841B |
| December 31, 2022 | 1.616B |
| September 30, 2022 | 2.143B |
| June 30, 2022 | 1.317B |
| March 31, 2022 | 1.476B |
| December 31, 2021 | 1.899B |
| September 30, 2021 | 1.884B |
| June 30, 2021 | 464.00M |
| March 31, 2021 | 1.646B |
| December 31, 2020 | 1.615B |
| September 30, 2020 | 2.021B |
| June 30, 2020 | 1.803B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.825B |
| December 31, 2019 | 1.703B |
| September 30, 2019 | 1.968B |
| June 30, 2019 | 2.179B |
| March 31, 2019 | 1.992B |
| December 31, 2018 | 1.928B |
| September 30, 2018 | 1.859B |
| June 30, 2018 | 2.296B |
| March 31, 2018 | 2.311B |
| December 31, 2017 | -4.264B |
| September 30, 2017 | 2.021B |
| June 30, 2017 | 2.151B |
| March 31, 2017 | 2.071B |
| December 31, 2016 | 1.935B |
| September 30, 2016 | 2.017B |
| June 30, 2016 | 1.87B |
| March 31, 2016 | 1.90B |
| December 31, 2015 | 1.80B |
| September 30, 2015 | 1.863B |
| June 30, 2015 | 1.653B |
| March 31, 2015 | 1.623B |
| December 31, 2014 | 1.294B |
| September 30, 2014 | 1.244B |
| June 30, 2014 | 1.547B |
| March 31, 2014 | 1.073B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.50B |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
| AbbVie, Inc. | 3.604B |
| Biogen, Inc. | 97.50M |
| Vertex Pharmaceuticals, Inc. | 1.100B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.07B |
| Total Expenses (Quarterly) | 7.692B |
| EPS Diluted (Quarterly) | 4.366 |
| Enterprise Value | 280.82B |
| Gross Profit Margin (Quarterly) | 72.08% |
| Profit Margin (Quarterly) | 23.59% |
| Earnings Yield | 3.63% |
| Operating Earnings Yield | 5.28% |
| Normalized Earnings Yield | 3.975 |